All In Biotech

Drug Trial Radar · NCT05219617

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Carisbamate (YKP509) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults, With Optional Open-Label Extension

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 252 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

252

Planned (sponsor's estimate)

Start

Apr 28, 2022

Primary completion

Feb 2027

Study completion Dec 2028

Sponsor

Lead sponsor
SK Life Science, Inc.Industry
Sponsor type
Industry
First posted
Feb 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate the efficacy of carisbamate (YKP509) as adjunctive treatment in reducing the number of drop seizures (tonic, atonic, and tonic-clonic) compared with placebo in pediatric and adult subjects (age 4-55 years) diagnosed with Lennox Gastaut Syndrome (LGS).

Conditions

  • Seizures
  • Lennox Gastaut Syndrome

Interventions

  • CarisbamateDrug

    Adolescent subjects 12 to 18 years old will receive the same dose as adults. Subjects 4 to \< 12 years old in the carisbamate 200 mg BID arm will receive 4 mg/kg BID (not to exceed 200 mg BID \[or a total of 400 mg per day\]). Subjects 4 to \< 12 years old in the carisbamate 300 mg BID arm will receive 5.5 mg/kg BID (not to exceed 300 mg BID \[or a total of 600 mg per day\]).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary outcome will be the percentage change from baseline in the total frequency (average per 28 days) of countable drop seizures with potential to fall (tonic, atonic, tonic-clonic) seizures during the double-blind treatment period.Time frame: 3 years

Locations

71 sites in 16 countries. Site status is shown where the registry gives one.

  • Stanford University Hospital

    Palo Alto, California · Recruiting

  • University of Florida Health Science Center

    Jacksonville, Florida · Completed

  • AdventHealth

    Orlando, Florida · Completed

  • Pediatric Epilepsy and Neurology Specialists

    Tampa, Florida · Recruiting

  • University of South Florida

    Tampa, Florida · Completed

  • Axcess Medical Research

    Wellington, Florida · Completed

  • Consultants in Epilepsy and Neurology PLLC

    Boise, Idaho · Completed

  • Bluegrass Epilepsy Research, LLC

    Lexington, Kentucky · Completed

  • University Medical Center New Orleans

    New Orleans, Louisiana · Completed

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Completed

  • University of Missouri School of Medicine

    Columbia, Missouri · Completed

  • Northeast Regional Epilepsy Group

    Hackensack, New Jersey · Recruiting

  • St. Peters Hospital

    New Brunswick, New Jersey · Completed

  • Montefiore

    The Bronx, New York · Completed

  • Duke University Clinical Research at Pickett Road

    Durham, North Carolina · Recruiting

  • Wake Forest University - School of Medicine

    Winston-Salem, North Carolina · Completed

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Austin Epilepsy Care Center - Clinic/Outpatient Facility

    Austin, Texas · Completed

  • Neurology Consultants of Dallas, PA - Hospital

    Dallas, Texas · Completed

  • Virginia Epilepsy and Neurodevelopmental Clinic at WNC

    Winchester, Virginia · Completed

  • Hospital de Ninos de La Santisma Trinidad

    Córdoba, Córdoba Province, Argentina · Completed

  • Resolution Psychopharmacology Research Institute

    Mendoza, Mendoza Province, Argentina · Completed

  • Austin Hosptial

    Heidelberg, Australia · Recruiting

  • Alfred Health

    Melbourne, Australia · Recruiting

  • Perth's Children Hospital

    Nedlands, Australia · Completed

  • Queensland Children's Hospital

    South Brisbane, Australia · Completed

  • Fundacion Hospital Universidad del Norte

    Barranquilla, Colombia · Withdrawn

  • Fundacion Valle del Lili/Clinic - Outpatient

    Cali, Colombia · Withdrawn

  • CliniSalud del Sur S.A.S - Centro de Investigación

    Envigado, Colombia · Completed

  • Hospital Pabloe Tubon Uribe

    Medellín, Colombia · Completed

  • Institutio Neurologico de Colombia

    Medellín, Colombia · Completed

  • Universitatsklinikum Erangen

    Erlangen, Bavaria, Germany · Recruiting

  • Kleinwachau Sächsisches Epilepsiezentrum

    Radeberg, Saxony, Germany · Recruiting

  • Iaso Children's Hospital

    Marousi, Attica, Greece · Completed

  • Orszagos Mentalis, Ideggyogyaszati es Idegsebezeti Intezet

    Budapest, Hungary · Completed

  • Semmelweis Egyetem Idegsebeszeti es Neurointervencios Klinika

    Budapest, Hungary · Recruiting

  • Soroka University Medical Centre

    Beersheba, Israel · Completed

  • Hadassah Medical Center

    Jerusalem, Israel · Completed

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.